Mark Raffeld
National Institutes of Health
455 Papers
7K Citations
Mark Raffeld is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lymphoma & Medicine. The author has an hindex of 101, co-authored 418 publications. Previous affiliations of Mark Raffeld include City of Hope National Medical Center & Center for Biologics Evaluation and Research.
Chat about Author
Papers
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley,John R. Wunderlich,Paul F. Robbins,James Chih-Hsin Yang,Patrick Hwu,Douglas J. Schwartzentruber,Suzanne L. Topalian,Richard M. Sherry,Nicholas P. Restifo,Amy M. Hubicki,Michael R. Robinson,Mark Raffeld,Paul H. Duray,Claudia A. Seipp,Linda Rogers-Freezer,Kathleen E. Morton,Sharon Mavroukakis,Donald E. White,Steven A. Rosenberg +18 more
TL;DR: The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
Gene-Expression Profiles in Hereditary Breast Cancer
Ingrid Hedenfalk,David Duggan,Yi Chen,Michael D. Radmacher,M. Bittner,Richard M. Simon,P. Meltzer,Barry A. Gusterson,Manel Esteller,O. P. Kallioniemi,Benjamin S. Wilfond,Åke Borg,J.M. Trent,Mark Raffeld,Zohar Yakhini,Amir Ben-Dor,Edward R. Dougherty,Juha Kononen,Lukas Bubendorf,W Fehrle,Stefania Pittaluga,Sofia Gruvberger,Niklas Loman,Oskar T. Johannsson,Håkan Olsson,Guido Sauter +25 more
TL;DR: Significantly different groups of genes are expressed by breast cancers with BRCA1 mutations and breast cancersWith BRCa2 mutations, the results suggest that a heritable mutation influences the gene-expression profile of the cancer.
1.7K
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins,Richard A. Morgan,Steven A. Feldman,James Chih-Hsin Yang,Richard M. Sherry,Mark E. Dudley,John R. Wunderlich,Azam V. Nahvi,Lee J. Helman,Crystal L. Mackall,Udai S. Kammula,Michael S. Hughes,Nicholas P. Restifo,Mark Raffeld,Chyi-Chia Richard Lee,Catherine Levy,Yong F. Li,Mona El-Gamil,Susan L. Schwarz,Carolyn M. Laurencot,Steven A. Rosenberg +20 more
TL;DR: These observations indicate that TCR-based gene therapies directed against NY-ESO-1 represent a new and effective therapeutic approach for patients with melanoma and synovial cell sarcoma.
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer,Mark E. Dudley,Sadik H. Kassim,Robert Somerville,Robert O. Carpenter,Maryalice Stetler-Stevenson,James Chih-Hsin Yang,Giao Q. Phan,Michael S. Hughes,Richard M. Sherry,Mark Raffeld,Steven R. Feldman,Lily Lu,Yong F. Li,Lien T. Ngo,Andre Goy,Tatyana Feldman,David Spaner,Michael L. Wang,Clara C. Chen,Sarah M. Kranick,Avindra Nath,Debbie-Ann N. Nathan,Kathleen E. Morton,Mary Ann Toomey,Steven A. Rosenberg +25 more
TL;DR: The results demonstrate the feasibility and effectiveness of treating chemotherapy-refractory B-cell malignancies with anti-CD19 CAR T cells and provide strong support for further development of this approach.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer,Wyndham H. Wilson,John E. Janik,Mark E. Dudley,Maryalice Stetler-Stevenson,Steven A. Feldman,Irina Maric,Mark Raffeld,Debbie Ann N. Nathan,Brock J. Lanier,Richard A. Morgan,Steven A. Rosenberg +11 more
TL;DR: A patient with advanced follicular lymphoma was treated by administering a preparative chemotherapy regimen followed by autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) that recognized the B- cell antigen CD19, and B-cell precursors were selectively eliminated from the patient's bone marrow after infusion of anti-CD19-CAR-transduced T cells.
1.3K